DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Jørgensen KK, Olsen IC, Goll GL. et al.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial.
Lancet 2017;
389: 2304-2316
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.